Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
candesartan + felodipine
- Development stage
- Phase 4
- Lead developer
- AstraZeneca
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Candesartan + felodipine** is a fixed-dose combination of two antihypertensive agents: candesartan, an angiotensin II type 1 receptor blocker (ARB), and felodipine, a dihydropyridine calcium channel blocker. This combination is designed to provide additive blood pressure lowering effects for the treatment of hypertension, particularly in patients whose blood pressure is not adequately controlled by monotherapy. Candesartan selectively blocks the vasoconstrictive and aldosterone-secreting effects of angiotensin II, while felodipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation. The combination has demonstrated additive efficacy and a favorable tolerability profile in clinical studies[1][3][4].
- Other names
- candesartan + felodipine
02
Targets
AGTR1 (Angiotensin II Type-1 receptor)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)LTCC (Voltage-gated calcium channel (L-type))
Beyond the preview
Go deeper on candesartan + felodipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on candesartan + felodipine.